P. Lortholary, CHRONIC LYMPHOID LEUKEMIA SECONDARILY ASSOCIATED WITH A MALIGNANT RETICULOPATHY

, Hématologie, vol.4, pp.621-644, 1964.

S. Molica, A systematic review on Richter syndrome: what is the published evidence?, Leuk. Lymphoma, vol.51, pp.415-421, 2010.

D. Rossi and G. Gaidano, Richter syndrome: molecular insights and clinical perspectives, Hematol. Oncol, vol.27, pp.1-10, 2009.

S. Aydin, CD38 gene polymorphism and chronic lymphocytic leukemia: a role in transformation to Richter syndrome?, Blood, vol.111, pp.5646-5653, 2008.

A. Tsimberidou, Clinical outcomes and prognostic factors in patients with Richter"s syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.24, pp.2343-2351, 2006.

D. Rossi, The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation, Blood, vol.117, pp.3391-3401, 2011.

B. Timár, Relationship between the mutational status of VH genes and pathogenesis of diffuse large B-cell lymphoma in Richter"s syndrome, Leukemia, vol.18, pp.326-330, 2004.

D. X. Rossi, Molecular pathogenesis of transformed lymphomas, Hematol. Oncol, vol.33, issue.1, pp.70-74, 2015.

J. Jelicic, The Role of Lymphocyte to Monocyte Ratio, Microvessel Density and HiGH CD44 Tumor Cell Expression in Non Hodgkin Lymphomas, Pathol. Oncol. Res. POR, vol.22, pp.567-577, 2016.

Y. Oki, Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients" survival benefit from rituximab, Eur. J. Haematol, vol.81, pp.448-453, 2008.

S. J. Wölfle, PD-L1 expression on tolerogenic APCs is controlled by STAT-3, Eur. J. Immunol, vol.41, pp.413-424, 2011.

E. Campo, The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications, Blood, vol.117, pp.5019-5032, 2011.

C. P. Hans, Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray, Blood, vol.103, pp.275-282, 2004.

A. Rosenwald, The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma, N. Engl. J. Med, vol.346, pp.1937-1947, 2002.

T. Lu, Immunohistochemical algorithm alone is not enough for predicting the outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP, Int. J. Clin. Exp. Pathol, vol.8, pp.275-286, 2015.

W. Xing, PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications, Oncotarget, 2016.

J. J. Van-dongen, Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT983936, Leukemia, vol.17, pp.2257-2317, 2003.

T. Tadmor, Richter"s transformation to diffuse large B-cell lymphoma: a retrospective study reporting clinical data, outcome, and the benefit of adding rituximab to chemotherapy, from the Israeli CLL Study Group, Am. J. Hematol, vol.89, pp.218-222, 2014.

, A predictive model for aggressive non-Hodgkin"s lymphoma. The International NonHodgkin"s Lymphoma Prognostic Factors Project, N. Engl. J. Med, vol.329, pp.987-994, 1993.

M. Solh, The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011), Leuk. Lymphoma, vol.54, pp.252-254, 2013.

E. Giné, Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia ("accelerated" chronic lymphocytic leukemia) with aggressive clinical behavior, Haematologica, vol.95, pp.1526-1533, 2010.

O. Benjamini, Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes, Leuk. Lymphoma, vol.56, pp.1643-1650, 2015.

O. Hamid, Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma, N. Engl. J. Med, vol.369, pp.134-144, 2013.

S. L. Topalian, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N. Engl. J. Med, vol.366, pp.2443-2454, 2012.

S. M. Ansell, PD-1 blockade with nivolumab in relapsed or refractory Hodgkin"s lymphoma, N. Engl. J. Med, vol.372, pp.311-319, 2015.

J. Kiyasu, Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma, Blood, vol.126, pp.2193-2201, 2015.

T. Menter, A. Bodmer-haecki, S. Dirnhofer, and A. Tzankov, Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas, Hum. Pathol, vol.54, pp.17-24, 2016.

B. J. Chen, PD-L1 Expression is Characteristic of a Subset of Aggressive B-Cell Lymphomas and Virus-Associated Malignancies, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res, vol.19, pp.3462-3473, 2013.

D. Rossille, High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial, Leukemia, vol.28, pp.2367-2375, 2014.
URL : https://hal.archives-ouvertes.fr/hal-00981338

Y. Xia, L. Jeffrey-medeiros, and K. H. Young, Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies, Biochim. Biophys. Acta, vol.1865, pp.58-71, 2016.

L. Marcheselli, Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi, Br. J. Haematol, vol.169, pp.544-551, 2015.

F. Sallusto, D. Lenig, R. Förster, M. Lipp, and A. Lanzavecchia, Two subsets of memory T lymphocytes with distinct homing potentials and effector functions, Nature, vol.401, pp.708-712, 1999.

J. Reiser, A. Banerjee, and . Effector, Memory, and Dysfunctional CD8+ T Cell Fates in the Antitumor Immune Response, J. Immunol. Res, 2016.
DOI : 10.1155/2016/8941260

URL : http://downloads.hindawi.com/journals/jir/2016/8941260.pdf

N. Wada, Tumour-associated macrophages in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group, Histopathology, vol.60, pp.313-319, 2012.

F. Marchesi, High density of CD68+/CD163+ tumour-associated macrophages (M2-TAM) at diagnosis is significantly correlated to unfavorable prognostic factors and to poor clinical outcomes in patients with diffuse large B-cell lymphoma, Hematol. Oncol, vol.33, pp.110-112, 2015.

A. Mantovani, A. Sica, and M. Locati, New vistas on macrophage differentiation and activation, Eur. J. Immunol, vol.37, pp.14-16, 2007.
DOI : 10.1002/eji.200636910

URL : http://onlinelibrary.wiley.com/doi/10.1002/eji.200636910/pdf

A. A. Alizadeh, Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling, Nature, vol.403, pp.503-511, 2000.
DOI : 10.1038/35000501

T. M. Cardesa-salzmann, High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy, Haematologica, vol.96, pp.996-1001, 2011.
DOI : 10.3324/haematol.2010.037408

URL : http://www.haematologica.org/content/haematol/96/7/996.full.pdf

J. C. Gomez-gelvez, M. E. Salama, S. L. Perkins, M. Leavitt, and K. V. Inamdar, Prognostic Impact of Tumor Microenvironment in Diffuse Large B-Cell Lymphoma Uniformly Treated With R-CHOP Chemotherapy, Am. J. Clin. Pathol, vol.145, pp.514-523, 2016.

P. G. Isaacson, The revised European-American lymphoma (REAL) classification, Clin Oncol (R Coll Radiol), vol.7, issue.6, pp.347-355, 1995.
DOI : 10.1016/s0936-6555(05)80003-2

E. Campo, S. H. Swerdlow, N. L. Harris, S. Pileri, H. Stein et al., The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications, Blood, vol.117, pp.5019-5051, 2011.
DOI : 10.1182/blood-2011-01-293050

URL : http://www.bloodjournal.org/content/117/19/5019.full.pdf

L. Guyader-peyrou, S. Belot, A. Maynadié, M. Binder-foucard, F. Remontet et al., Cancer incidence in France over the 1980-2012 period: Hematological malignancies, Rev Epidemiol Sante Publique, vol.64, issue.2, pp.103-115, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01511580

M. Engelhard, G. Brittinger, D. Huhn, H. H. Gerhartz, P. Meusers et al., Subclassification of diffuse large B-cell lymphomas according to the Kiel classification: distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factor, Blood, vol.89, issue.7, pp.2291-2298, 1997.

E. Haralambieva, K. A. Pulford, L. Lamant, S. Pileri, G. Roncador et al., Anaplastic large-cell lymphomas of B-cell phenotype are anaplastic lymphoma kinase (ALK) negative and belong to the spectrum of diffuse large B-cell lymphomas, Br J Haematol, vol.109, issue.3, pp.584-91, 2000.

D. Cunningham, E. A. Hawkes, A. Jack, W. Qian, P. Smith et al., Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles, Lancet, vol.381, issue.9880, pp.1817-1843, 2013.

B. Coiffier, C. Thieblemont, E. Van-den-neste, G. Lepeu, I. Plantier et al., Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d"Etudes des Lymphomes de l, Adulte. Blood, vol.116, issue.12, pp.2040-2045, 2010.

B. Coiffier, State-of-the-art therapeutics: diffuse large B-cell lymphoma, J Clin Oncol, vol.23, issue.26, pp.6387-93, 2005.

P. P. Carbone, H. S. Kaplan, K. Musshoff, D. W. Smithers, and M. Tubiana, Report of the Committee on Hodgkin"s Disease Staging Classification, Cancer Res, vol.31, issue.11, pp.1860-1861, 1971.

L. H. Sehn, B. Berry, M. Chhanabhai, C. Fitzgerald, K. Gill et al., The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood, vol.109, pp.1857-61, 2007.

J. W. Baars, D. De-jong, E. M. Willemse, L. Gras, O. Dalesio et al., Diffuse large B-cell non-Hodgkin lymphomas: the clinical relevance of histological subclassification, Br J Cancer, vol.79, pp.1770-1776, 1999.

Y. Xu, S. H. Kroft, R. W. Mckenna, and D. B. Aquino, Prognostic significance of tumour-infiltrating T lymphocytes and T-cell subsets in de novo diffuse large B-cell lymphoma: a multiparameter flow cytometry study, Br J Haematol, vol.112, issue.4, pp.945-954, 2001.

L. Yan, Y. Liu, D. Luo, F. Zhang, Y. Cheng et al., MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified, PLoS ONE, vol.9, issue.8, p.104068, 2014.

C. Copie-bergman, P. Cuillière-dartigues, M. Baia, J. Briere, R. Delarue et al., MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study, Blood, vol.126, issue.22, pp.2466-74, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01543654

A. A. Alizadeh, M. B. Eisen, R. E. Davis, C. Ma, I. S. Lossos et al., Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling, Nature, vol.403, issue.6769, pp.503-514, 2000.

A. Rosenwald, G. Wright, W. C. Chan, J. M. Connors, E. Campo et al., The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma, N Engl J Med, vol.346, issue.25, pp.1937-1984, 2002.

S. Guney, F. Jardin, P. Bertrand, S. Mareschal, F. Parmentier et al., Several mechanisms lead to the inactivation of the CDKN2A (P16), P14ARF, or CDKN2B (P15) genes in the GCB and ABC molecular DLBCL subtypes, Genes Chromosomes Cancer, vol.51, issue.9, pp.858-67, 2012.

F. Jardin, J. Jais, T. Molina, F. Parmentier, J. Picquenot et al., Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study, Blood, vol.116, issue.7, pp.1092-104, 2010.
URL : https://hal.archives-ouvertes.fr/ensl-00816038

C. P. Hans, D. D. Weisenburger, T. C. Greiner, R. D. Gascoyne, J. Delabie et al., Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray, Blood, vol.103, issue.1, pp.275-82, 2004.

W. Choi, D. D. Weisenburger, T. C. Greiner, M. A. Piris, A. H. Banham et al., A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy, Clin Cancer Res, vol.15, issue.17, pp.5494-502, 2009.

P. N. Meyer, K. Fu, T. C. Greiner, L. M. Smith, J. Delabie et al., Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab, J Clin Oncol, vol.29, issue.2, pp.200-207, 2011.

H. Takahashi, K. Miura, M. Nakagawa, M. Sugitani, Y. Amano et al., Negative impact of concurrent overexpression of MYC and BCL2 in patients with advanced diffuse large B-cell lymphoma treated with dose-intensified immunochemotherapy, Leuk Lymphoma, pp.1-7, 2016.

N. A. Johnson, G. W. Slack, K. J. Savage, J. M. Connors, S. Ben-neriah et al., Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone, J Clin Oncol, vol.30, issue.28, pp.3452-3461, 2012.

J. Wang, M. Zhou, J. Xu, B. Chen, and J. Ouyang, Combination of BCL-2 and MYC protein expression improves high-risk stratification in diffuse large B-cell lymphoma, Onco Targets Ther, vol.8, pp.2645-50, 2015.

P. Jain, L. E. Fayad, A. Rosenwald, K. H. Young, O. Brien et al., Recent advances in de novo CD5+ diffuse large B cell lymphoma, Am J Hematol, vol.88, issue.9, pp.798-802, 2013.

Z. Y. Xu-monette, B. S. Dabaja, X. Wang, M. Tu, G. C. Manyam et al., Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP, Mod Pathol, vol.28, issue.12, pp.1555-73, 2015.

T. Lu, Q. Gong, L. Wang, L. Fan, X. Zhang et al., Immunohistochemical algorithm alone is not enough for predicting the outcome of patients with diffuse large Bcell lymphoma treated with R-CHOP, Int J Clin Exp Pathol, vol.8, issue.1, pp.275-86, 2015.

M. Abdulla, S. Laszlo, J. Triumf, G. Hedström, M. Berglund et al., A populationbased study of cellular markers in R-CHOP treated diffuse large B-cell lymphoma patients, Acta Oncol, pp.1-6, 2016.

T. Igawa, Y. Sato, K. Takata, N. Iwaki, T. Tanaka et al., De novo CD5-positive diffuse large B-cell lymphomas show high specificity for cyclin D2 expression, Diagn Pathol, vol.8, p.81, 2013.

S. D. Dojcinov, G. Venkataraman, S. Pittaluga, I. Wlodarska, J. A. Schrager et al., Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma, Blood, vol.117, issue.18, pp.4726-4761, 2011.

J. Jelicic, M. T. Balint, M. P. Jovanovic, N. Boricic, M. Micev et al., The Role of Lymphocyte to Monocyte Ratio, Microvessel Density and HiGH CD44 Tumor Cell Expression in Non Hodgkin Lymphomas, Pathol Oncol Res, vol.22, issue.3, pp.567-77, 2016.

Y. Xia, J. Medeiros, L. Young, and K. H. , Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies, Biochim Biophys Acta, issue.1, pp.58-71, 1865.

J. Kiyasu, H. Miyoshi, A. Hirata, F. Arakawa, A. Ichikawa et al., Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma, Blood, vol.126, pp.2193-201, 2015.

L. K. Jørgensen, M. Ø. Poulsen, M. B. Laursen, S. C. Marques, H. E. Johnsen et al., MicroRNAs as novel biomarkers in diffuse large B-cell lymphoma-a systematic review, Dan Med J, vol.62, issue.5, 2015.

, SEER Cancer Statistics Review 1975-2001-Previous Version-SEER Cancer Statistics

J. Delgado and N. Villamor, Chronic lymphocytic leukemia in young individuals revisited, Haematologica, vol.99, issue.1, pp.4-5, 2014.

C. Marwick, Link found between Agent Orange and chronic lymphocytic leukaemia, BMJ, vol.326, issue.7383, p.242, 2003.

T. Zenz, D. Mertens, R. Küppers, H. Döhner, and S. Stilgenbauer, From pathogenesis to treatment of chronic lymphocytic leukaemia, Nat Rev Cancer, vol.10, issue.1, pp.37-50, 2010.

L. R. Goldin, S. L. Slager, and N. E. Caporaso, Familial Chronic Lymphocytic Leukemia, Curr Opin Hematol, vol.17, issue.4, pp.350-355, 2010.

M. Hallek, B. D. Cheson, D. Catovsky, F. Caligaris-cappio, G. Dighiero et al., Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines, Blood, vol.111, issue.12, pp.5446-56, 2008.

E. Matutes, K. Owusu-ankomah, R. Morilla, G. Marco, J. Houlihan et al., The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL, Leukemia, vol.8, issue.10, pp.1640-1645, 1994.

A. Carbone, A. Pinto, A. Gloghini, R. Volpe, and V. Zagonel, B-zone small lymphocytic lymphoma: a morphologic, immunophenotypic, and clinical study with comparison to "well-differentiated" lymphocytic disorders, Hum Pathol, vol.23, issue.4, pp.438-486, 1992.

F. R. Dick and R. D. Maca, The lymph node in chronic lymphocytic leukemia, Cancer, vol.41, issue.1, pp.283-92, 1978.

G. A. Pangalis, M. K. Angelopoulou, T. P. Vassilakopoulos, M. P. Siakantaris, and C. Kittas, Bchronic lymphocytic leukemia, small lymphocytic lymphoma, and lymphoplasmacytic lymphoma, including Waldenström"s macroglobulinemia: a clinical, morphologic, and biologic spectrum of similar disorders, Semin Hematol, vol.36, issue.2, pp.104-118, 1999.

C. Schmid and P. G. Isaacson, Proliferation centres in B-cell malignant lymphoma, lymphocytic (B-CLL): an immunophenotypic study, Histopathology, vol.24, issue.5, pp.445-51, 1994.

K. R. Rai, A. Sawitsky, E. P. Cronkite, A. D. Chanana, R. N. Levy et al., Clinical staging of chronic lymphocytic leukemia, Blood, vol.46, issue.2, pp.219-253, 1975.

J. L. Binet, A. Auquier, G. Dighiero, C. Chastang, H. Piguet et al., A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis, Cancer, vol.48, issue.1, pp.198-206, 1981.

P. Panayiotidis and P. Kotsi, Genetics of small lymphocyte disorders, Semin Hematol, vol.36, issue.2, pp.171-178, 1999.

G. A. Calin, M. Ferracin, A. Cimmino, D. Leva, G. Shimizu et al., A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia, N Engl J Med, vol.353, issue.17, pp.1793-801, 2005.

Y. L. Kwong, J. Pang, L. M. Ching, H. W. Liu, R. H. Liang et al., Trisomy 12 in chronic lymphocytic leukemia. An interphase cytogenetic study by fluorescence in situ hybridization, Cancer Genet Cytogenet, vol.72, issue.2, pp.83-88, 1994.

D. Mertens and S. Stilgenbauer, Prognostic and predictive factors in patients with chronic lymphocytic leukemia: relevant in the era of novel treatment approaches?, J Clin Oncol, vol.32, issue.9, pp.869-72, 2014.

H. Döhner, S. Stilgenbauer, M. R. James, A. Benner, T. Weilguni et al., 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis, Blood, vol.89, issue.7, pp.2516-2538, 1997.

D. G. Oscier, A. C. Gardiner, S. J. Mould, S. Glide, Z. A. Davis et al., Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors, Blood, vol.100, issue.4, pp.1177-84, 2002.

A. Wiestner, A. Rosenwald, T. S. Barry, G. Wright, R. E. Davis et al., ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile, Blood, vol.15, issue.12, pp.4944-51, 2003.

J. Dürig, M. Naschar, U. Schmücker, K. Renzing-köhler, T. Hölter et al., CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia, Leukemia, vol.16, issue.1, pp.30-35, 2002.

S. Molica, A systematic review on Richter syndrome: what is the published evidence? Leuk Lymphoma, vol.51, pp.415-436, 2010.

P. Lortholary, M. Boiron, P. Ripault, J. P. Levy, A. Manus et al., Nouv Rev Fr Hematol, vol.4, pp.621-665, 1964.

A. Tsimberidou, O. Brien, S. Kantarjian, H. M. Koller, C. Hagemeister et al., Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience, Cancer, vol.107, issue.6, pp.1294-302, 2006.

J. Nitin, New Developments in Richter Syndrome, 2016.

D. Rossi and G. Gaidano, Richter syndrome: molecular insights and clinical perspectives, Hematol Oncol, vol.27, issue.1, pp.1-10, 2009.

S. Aydin, D. Rossi, L. Bergui, D. Arena, G. Ferrero et al., CD38 gene polymorphism and chronic lymphocytic leukemia: a role in transformation to Richter syndrome? Blood, vol.111, pp.5646-53, 2008.

M. Solh, K. R. Rai, B. L. Peterson, J. E. Kolitz, F. R. Appelbaum et al., The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011), Leuk Lymphoma, vol.54, issue.2, pp.252-256, 2013.

P. Jain, S. O"brien, and . Richter, s transformation in chronic lymphocytic leukemia, Oncology, vol.26, issue.12, pp.1146-52, 2012.

A. Tsimberidou, O. Brien, S. Khouri, I. Giles, F. J. Kantarjian et al., Clinical outcomes and prognostic factors in patients with Richter"s syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation, J Clin Oncol, vol.24, issue.15, pp.2343-51, 2006.

D. Rossi, V. Spina, C. Deambrogi, S. Rasi, L. Laurenti et al., The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation, Blood, vol.117, issue.12, pp.3391-401, 2011.

J. Van-dongen, A. W. Langerak, M. Brüggemann, P. Evans, .. S. Hummel et al., Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936, Leukemia, vol.17, issue.12, pp.2257-317, 2003.